Alchemab Therapeutics
London
About Alchemab Therapeutics
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $117.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2025)
- Website: alchemab.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/alchemab-therapeutics-120303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.